Gan & Lee Pharmaceuticals' Bi-weekly GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom China New York

Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0.99%; and at 30 weeks, participants' body weight continued to decrease.The clinical efficacy and safety of bi-weekly 48 mg and once-weekly 24 mg GZR18 injections were comparable, with no significant difference in mean percent change in body weight from baseline between the two groups (one-sided test, P > 0.025).GZR18 injections were safe and well tolerated, with the most commonly reported adverse events being gastrointestinal reactions, comparable to similar drugs.(Media)
[e-mail] (Business Development)

Photo - https://mma.prnewswire.com/media/2465774/image.jpg
Logo - https://mma.prnewswire.com/media/2439708/Gan_Lee_Pharmaceuticals_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/gan--lee-pharmaceuticals-bi-weekly-twice-a-month-glp-1-receptor-agonist-gzr18-injection-achieved-17-29-weight-loss-at-30-weeks-in-a-phase-iib-clinical-trial-302202579.html